7,718 results match your criteria Neuroprotective Agents in Stroke


Selenium nanoparticles for targeted stroke therapy through modulation of inflammatory and metabolic signaling.

Sci Rep 2019 Apr 15;9(1):6044. Epub 2019 Apr 15.

Physiology Research Center and Department of Physiology, Faculty of Medicine, Iran University of Medical Sciences, Tehran, Iran.

Ischemic cerebral stroke is a major cause of death and morbidity. Currently, no neuroprotective agents have been shown to impact the clinical outcomes in cerebral stroke cases. Here, we report therapeutic effects of Se nanoparticles on ischemic stroke in a murine model. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41598-019-42633-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6465364PMC
April 2019
1 Read

Design, synthesis and biological evaluation of chalcone analogues with novel dual antioxidant mechanisms as potential anti-ischemic stroke agents.

Acta Pharm Sin B 2019 Mar 7;9(2):335-350. Epub 2019 Jan 7.

Chemical Biology Research Center, School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou 325035, China.

Scavenging reactive oxygen species (ROS) by antioxidants is the important therapy to cerebral ischemia-reperfusion injury (CIRI) in stroke. The antioxidant with novel dual-antioxidant mechanism of directly scavenging ROS and indirectly through antioxidant pathway activation may be a promising CIRI therapeutic strategy. In our study, a series of chalcone analogues were designed and synthesized, and multiple potential chalcone analogues with dual antioxidant mechanisms were screened. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.apsb.2019.01.003DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6437665PMC
March 2019
2 Reads

Repurposing of the β-Lactam Antibiotic, Ceftriaxone for Neurological Disorders: A Review.

Front Neurosci 2019 26;13:236. Epub 2019 Mar 26.

Department of Pharmacology and Toxicology, School of Pharmacy, College of Health Sciences, Mekelle University, Mekelle, Ethiopia.

To date, there is no cure or disease-modifying agents available for most well-known neurological disorders. Current therapy is typically focused on relieving symptoms and supportive care in improving the quality of life of affected patients. Furthermore, the traditional drug discovery technique is more challenging, particularly for neurological disorders. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fnins.2019.00236DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6444273PMC
March 2019
2 Reads

GLP-1's role in neuroprotection: a systematic review.

Brain Inj 2019 Apr 2:1-85. Epub 2019 Apr 2.

a School of Medicine , Koç University , Istanbul , Turkey.

Glucagon-like peptide 1 (GLP-1) is a target for treatment of diabetes; however, its function in the brain is not well studied. In this systematic review, we aimed to analyze the neuroprotective role of GLP-1 and its defined mechanisms.

Methods: We searched 'Web of Science' and 'Pubmed' to identify relevant studies using GLP-1 as the keyword. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/02699052.2019.1587000DOI Listing
April 2019
2 Reads

Protective properties of the aqueous extract of saffron (Crocus sativus L.) in ischemic stroke, randomized clinical trial.

J Ethnopharmacol 2019 Mar 23;238:111833. Epub 2019 Mar 23.

Neuroscience Research Centre, Baqiyatallah University of Medical Sciences, Tehran, Iran. Electronic address:

Ethnopharmacological Relevance: Crocus sativus L. has been used throughout the world in traditional medicine as a treatment for neurological disorders such as depression. Growing attention is currently being paid to the use of neuroprotective agents in ischemic strokes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jep.2019.111833DOI Listing

Pooled analysis suggests benefit of catheter-based hematoma removal for intracerebral hemorrhage.

Neurology 2019 Apr 20;92(15):e1688-e1697. Epub 2019 Mar 20.

From the Michael E. DeBakey VA Medical Center Stroke Program (P.M., N.S.) and Analytical Software and Engineering Research Laboratory, Department of Neurology (P.M., N.S., T.A.K.), Baylor College of Medicine, Houston, TX; Department of Neurology (S.B.M.) and Clinical and Translational Neuroscience Unit (S.B.M.), Feil Family Brain and Mind Research Institute, Weill Cornell Medicine, New York, NY; APHP (Y.S.), Urgences Cerebro-Vasculaire, Pitié-Salpêtrière, and UPMC Paris Sorbonne Universités (Y.S.), Paris, France; Departments of Statistics and Bioengineering (M.K.) and Chemistry (T.A.K.), Rice University, Houston; Institute of Biosciences and Technology (IBT) (T.A.K.), Texas A&M Health Science Center-Houston Campus; and Department of Neurology (T.A.K.), Houston Methodist Hospital and Research Institute, TX.

Objective: To develop models of outcome for intracerebral hemorrhage (ICH) to identify promising and futile interventions based on their early phase results without need for correction for baseline imbalances.

Methods: We developed a pooled outcome model from the control arms of randomized control trials and tested different interventions against the model at comparable baseline conditions. Eligible clinical trials and large case series were identified from multiple library databases. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1212/WNL.0000000000007269DOI Listing
April 2019
2 Reads

Intravenous Magnesium Sulfate in Acute Stroke.

Stroke 2019 Apr;50(4):931-938

Division of Cerebrovascular Diseases, Department of Neurology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA(V.-A.L.).

Background and Purpose- Acute stroke treatment is challenging, and stroke remains a major cause of death and disability. The purpose of this meta-analysis is to investigate the effects of postacute stroke intravenous administration of the neuroprotectant magnesium sulfate (MgSO) on global outcome, functional outcome, and mortality 90 days poststroke (ischemic and nonischemic). Methods- We searched in Pubmed, Science Direct, CENTRAL, and ClinicalTrials. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1161/STROKEAHA.118.021916DOI Listing
April 2019
6 Reads

Applications of Liposomal Drug Delivery Systems to Develop Neuroprotective Agents for the Treatment of Ischemic Stroke.

Biol Pharm Bull 2019 ;42(3):319-326

Department of Medical Biochemistry, School of Pharmaceutical Sciences, University of Shizuoka.

Ischemic stroke is one of the leading causes of severe disability and death. In clinical settings, tissue plasminogen activator (t-PA) for thrombolytic therapy is the only globally approved drug for the treatment of ischemic stroke. However, the proportion of patients who receive t-PA therapy is extremely limited due to its narrow therapeutic time window (TTW) and the risk of cerebral hemorrhage. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1248/bpb.b18-00683DOI Listing
January 2019
1 Read

Expression of S100B Protein in Ischemia/Reperfusion-Induced Brain Injury After Cyclosporine Therapy: A Biochemical Serum Marker with Prognostic Value?

Med Sci Monit 2019 Mar 3;25:1637-1644. Epub 2019 Mar 3.

Laboratory for Experimental Surgery and Surgical Research "N.S Christeas", Medical School of Athens, Athens, Greece.

BACKGROUND Accumulating evidence has indicated that S100B protein may be involved in the pathophysiology of ischemia-reperfusion brain injury. Cyclosporine has been shown to have neuroprotective functions. This study investigated the effect of cyclosporine on S100B serum levels and the severity of brain tissue damage in a rat model of cerebral ischemia-reperfusion (I/R). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.12659/MSM.912810DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6410611PMC
March 2019
1 Read

Imaging outcome measures of neuroprotection and repair in MS: A consensus statement from NAIMS.

Neurology 2019 Mar 20;92(11):519-533. Epub 2019 Feb 20.

From the Division of Neurology (J.O.), St. Michael's Hospital, University of Toronto, Canada; Department of Neurology (J.O., P.A.C., B.D., D.S.R.), Johns Hopkins University, Baltimore, MD; Mellen Center for Multiple Sclerosis (D.O.), Cleveland Clinic, OH; Department of Neurology (C.A., D.P.), University of Southern California, Los Angeles; Department of Neurology (E.C.K.), Massachusetts General Hospital, Harvard Medical School, Boston; Translational Neuroradiology Unit (M.A., G.N., P.S., D.S.R.), National Institute of Neurological Disorders and Stroke, Bethesda, MD; Brain Imaging Centre (D.L.A., S.N.), Montreal Neurological Institute, McGill University, Canada; Departments of Neurology (R.B.) and Radiology (R.B.), Brigham and Women's Hospital, Harvard Medical School, Boston; Department of Biostatistics (C.C.), Johns Hopkins School of Public Health, Baltimore, MD; Department of Neurology (L.F.), University of Texas Health Science Center at Houston; Department of Neurology (S.G., Y.W.), Weill Cornell Medical College, Cornell University, Ithaca, NY; Department of Neurology (R.H.), University of California at San Francisco; Department of Neurology (M.I., A.T.), Mount Sinai Hospital, New York, NY; Division of Neurology, Department of Medicine (S.K., D.K.B.L.), Department of Radiology (S.K., D.K.B.L., A.R.), Department of Physics and Astronomy (S.K., A.R., A.T., Y.Y.), MS/MRI Research Group (S.K., D.K.B.L., A.T., Y.Y.), MRI Research Centre (S.K., D.K.B.L., A.R.), and Department of Pediatrics (A.R.), University of British Columbia, Vancouver, Canada; A. A. Martinos Center for Biomedical Imaging (C.M.), Department of Radiology, Massachusetts General Hospital, Boston; Centre for Functional and Metabolic Mapping (R.S.M.), Robarts Research Institute, Western University, London, CA; Department of Neurology (F.N.), University of Minnesota, Minneapolis; Advanced Imaging Research Center (W.R., D.S., I.T.), Oregon Health & Science University, Portland; Department of Biostatistics, Epidemiology, and Informatics (R.T.S.), University of Pennsylvania Perelman School of Medicine, Philadelphia; Division of Neuroradiology and Neurophysics (T.Y.), University College London Institute of Neurology, UK; Department of Radiology (Y.Z.) and Department of Clinical Neurosciences and Hotchkiss Brain Institute (Y.Z.), University of Calgary, Canada; and Department of Neurology (N.L.S.), Cedars-Sinai Medical Center, Los Angeles, CA.

Objective: To summarize current and emerging imaging techniques that can be used to assess neuroprotection and repair in multiple sclerosis (MS), and to provide a consensus opinion on the potential utility of each technique in clinical trial settings.

Methods: Clinicians and scientists with expertise in the use of MRI in MS convened in Toronto, Canada, in November 2016 at a North American Imaging in Multiple Sclerosis (NAIMS) Cooperative workshop meeting. The discussion was compiled into a manuscript and circulated to all NAIMS members in attendance. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1212/WNL.0000000000007099DOI Listing
March 2019
3 Reads

Neuroprotective Secondary Metabolite Produced by an Endophytic Fungus, Neosartorya fischeri JS0553, Isolated from Glehnia littoralis.

J Agric Food Chem 2019 Feb 11;67(7):1831-1838. Epub 2019 Feb 11.

College of Pharmacy and Innovative Drug Center , Duksung Women's University , Seoul 01369 , Republic of Korea.

Roots of Glehnia littoralis have been used to heal stroke as a traditional medicine. Even though many studies on this plant have been conducted, the secondary metabolites produced by its endophytes and their bioactivities have not been investigated thus far. Therefore, a new meroditerpenoid named sartorypyrone E (1) and eight known compounds (2-9) were isolated from extracts of cultured Neosartorya fischeri JS0553, an endophyte of G. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/acs.jafc.8b05481DOI Listing
February 2019
7 Reads

Clinical Effects of Early Edaravone Use in Acute Ischemic Stroke Patients Treated by Endovascular Reperfusion Therapy.

Stroke 2019 Mar;50(3):652-658

Department of Acute Critical Care and Disaster Medicine (M.E., Y.O.), Tokyo Medical and Dental University Graduate School of Medicine, Japan.

Background and Purpose- Although several clinical studies suggested the beneficial effects of edaravone in acute ischemic stroke, most were performed under settings that differ from those in the current treatment strategy, which has dramatically changed with progress in reperfusion therapies. This study aimed to evaluate the efficacy of edaravone in patients with acute ischemic stroke treated by emergent endovascular reperfusion therapy. Methods- We conducted a retrospective observational study using a national administrative database. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1161/STROKEAHA.118.023815DOI Listing
March 2019
1 Read

Vinpocetine in the treatment of poststroke cognitive dysfunction: A protocol for systematic review and meta-analysis.

Medicine (Baltimore) 2019 Feb;98(6):e13685

Department of Neurology, Fifth Central Hospital of Tianjin, Binhai Hospital of Peking University, Tianjin, 300450.

Background: Previous clinical trials have reported that vinpocetine can be used for the treatment of cognitive dysfunction. However, its efficacy is still inconclusive. In this systematic review study, we aim to assess its efficacy and safety for the treatment of poststroke cognitive dysfunction (PSCD). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MD.0000000000013685DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6380872PMC
February 2019
3 Reads

Incretin-Based Antihyperglycemic Agents for the Management of Acute Ischemic Stroke in Patients with Diabetes Mellitus: A Review.

Diabetes Ther 2019 Apr 6;10(2):429-435. Epub 2019 Feb 6.

First Propedeutic Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, AHEPA Hospital, Thessaloniki, Greece.

Diabetes mellitus (DM) is a major risk factor for ischemic stroke. Moreover, patients with DM suffer more severe strokes and have worse functional outcome following an acute stroke than patients without DM. In this context, data from animal studies and emerging evidence from clinical studies suggest that incretin-based antihyperglycemic agents might exert beneficial effects in patients with DM who suffer ischemic stroke. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13300-019-0580-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6437305PMC
April 2019
1 Read

Structural elements of a pH-sensitive inhibitor binding site in NMDA receptors.

Nat Commun 2019 01 18;10(1):321. Epub 2019 Jan 18.

WM Keck Structural Biology Laboratory, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, 11724, USA.

Context-dependent inhibition of N-methyl-D-aspartate (NMDA) receptors has important therapeutic implications for the treatment of neurological diseases that are associated with altered neuronal firing and signaling. This is especially true in stroke, where the proton concentration in the afflicted area can increase by an order of magnitude. A class of allosteric inhibitors, the 93-series, shows greater potency against GluN1-GluN2B NMDA receptors in such low pH environments, allowing targeted therapy only within the ischemic region. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41467-019-08291-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6338780PMC
January 2019
3 Reads

Percheron Infarction: Is It Just a Rare Cerebrovascular Variant or a Forewarning of Severe Multiple Posterior Circulation Infarcts.

J Stroke Cerebrovasc Dis 2019 Apr 14;28(4):e27-e29. Epub 2019 Jan 14.

Department of Neurology, The Second Xiangya Hospital of Central South University, Changsha, PR China. Electronic address:

Percheron infarction, arising from occlusion of the Artery of Percheron, is few, which can result in bilateral thalamic and mesencephalic infarctions. We herein showcase a confirmed case of the Percheron infarction at the admission day, in which the patient advanced into severe multiple posterior circulation infarcts, along with petechial hemorrhage within the infarcts, even given the right therapy without delay. It reminds us that whether we could or should take this special infarction as a forewarning of more harmful infarcts getting in the way, or at least a precaution of poor vessel condition. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jstrokecerebrovasdis.2018.12.042DOI Listing
April 2019
2 Reads

Neuroprotective Agents in the Intensive Care Unit: -Neuroprotective Agents in ICU.

J Pharmacopuncture 2018 Dec 31;21(4):226-240. Epub 2018 Dec 31.

Neurogenic Inflammation Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.

Neuroprotection or prevention of neuronal loss is a complicated molecular process that is mediated by various cellular pathways. Use of different pharmacological agents as neuroprotectants has been reported especially in the last decades. These neuroprotective agents act through inhibition of inflammatory processes and apoptosis, attenuation of oxidative stress and reduction of free radicals. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3831/KPI.2018.21.026DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6333194PMC
December 2018
9 Reads

Protection against stroke with glucagon-like peptide 1 receptor agonists: a systematic review and meta-analysis.

Eur J Neurol 2019 Apr 30;26(4):559-565. Epub 2019 Jan 30.

Department of Internal Medicine, School of Medicine, University of Ioannina, Ioannina, Greece.

In experimental stroke models pretreatment with the newly introduced antidiabetic agents, glucagon-like peptide 1 receptor (GLP-1R) agonists, has been shown to exert neuroprotective effects. Published evidence with regard to the effect of treatment with GLP-1R agonists on the risk of stroke was evaluated. Data from prospective randomized placebo-controlled trials up to October 2018 involving GLP-1R agonists which reported cardiovascular outcomes as primary end-points of efficacy and/or safety were meta-analysed. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/ene.13905
Publisher Site
http://dx.doi.org/10.1111/ene.13905DOI Listing
April 2019
2 Reads

YiQi Tongluo Granule against Cerebral Ischemia/Reperfusion Injury in Rats by Freezing GluN2B and CaMK II through NMDAR/ERK1/2 Signaling.

Chem Pharm Bull (Tokyo) 2019 Mar 28;67(3):244-252. Epub 2018 Dec 28.

Anhui Province Key Laboratory of Chinese Medicinal Formula, Anhui University of Chinese Medicine.

Yiqi Tongluo Granule (YQTL) is a kind of proprietary Chinese medicine, manufactured by China Shineway Pharmaceutical Group Ltd., under the authority of China Food and Drug Administration (CFDA) treating cardiovascular and cerebrovascular diseases such as ischemic stroke in China, however the underlying mechanism of YQTL on treating ischemic stroke has not been revealed. This study is aimed to evaluate the protective effect of YQTL on cerebral ischemia/reperfusion (I/R) injury and inquire into its underlying mechanisms. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1248/cpb.c18-00806DOI Listing
March 2019
2 Reads

Prolyl hydroxylase domain inhibitors: can multiple mechanisms be an opportunity for ischemic stroke?

Neuropharmacology 2019 Apr 20;148:117-130. Epub 2018 Dec 20.

UCD School of Biomolecular & Biomedical Science, UCD Conway Institute of Biomolecular & Biomedical Research, University College Dublin, Belfield, Dublin 4, Ireland. Electronic address:

Stroke and cerebrovascular disease are now the fifth most common cause of death behind other diseases such as heart, cancer and respiratory disease and accounts for approximately 40-50 fatalities per 100,000 people each year in the United States. Currently the only therapy for acute stroke, is intravenous administration of tissue plasminogen activator which was approved in 1996 by the FDA. Surprisingly no new treatments have come on the market since, although endovascular mechanical thrombectomy is showing promising results in trials. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00283908183067
Publisher Site
http://dx.doi.org/10.1016/j.neuropharm.2018.12.021DOI Listing
April 2019
21 Reads

Marine Compound Xyloketal B as a Potential Drug Development Target for Neuroprotection.

Mar Drugs 2018 Dec 19;16(12). Epub 2018 Dec 19.

Department of Surgery, Faculty of Medicine, University of Toronto, Toronto, ON M5S 1A8, Canada.

Xyloketal B is a natural compound isolated from the mangrove fungus, sp. in the South China Sea. In the past decade, studies have shown that xyloketal B exhibits anti-oxidative, anti-inflammatory, and anti-apoptotic abilities and may serve as a treatment for ischemic stroke. Read More

View Article

Download full-text PDF

Source
http://www.mdpi.com/1660-3397/16/12/516
Publisher Site
http://dx.doi.org/10.3390/md16120516DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6316771PMC
December 2018
6 Reads

Ceria Nanoparticles Synthesized With Aminocaproic Acid for the Treatment of Subarachnoid Hemorrhage.

Stroke 2018 Dec;49(12):3030-3038

From the Laboratory of Innovative Nanotechnology, Biomedical Research Institute and Department of Neurology, Seoul National University Hospital, Republic of Korea (H.-G.J., D.-W.K., D.Y.K., S.K.K., S.I.K., J.h.H., W.Y., C.K.K., S.-H.L.).

Background and Purpose- Despite early aneurysm repair and aggressive management for complications, subarachnoid hemorrhage (SAH) results in at least 25% mortality rate and 50% persistent neurological deficit. We investigated whether ceria nanoparticles which have potent antioxidative activities can protect against subarachnoid hemorrhage via attenuating fatal brain injuries. Methods- Uniform, 3 nm, water-dispersed ceria nanoparticles were prepared from short sol-gel reaction of cerium (III) ions with aminocaproic acid in aqueous phase. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1161/STROKEAHA.118.022631DOI Listing
December 2018
2 Reads

Overview on the Effects of -Acetylcysteine in Neurodegenerative Diseases.

Molecules 2018 Dec 13;23(12). Epub 2018 Dec 13.

IRCCS Centro Neurolesi "Bonino-Pulejo", Via Provinciale Palermo, Contrada Casazza, 98124 Messina, Italy.

-acetylcysteine (NAC), which is an acetylated cysteine compound, has aroused scientific interest for decades due to its important medical applications. It also represents a nutritional supplement in the human diet. NAC is a glutathione precursor and shows antioxidant and anti-inflammatory activities. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/molecules23123305DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6320789PMC
December 2018

Neuroprotective agents in Acute Ischemic Stroke-A Reality Check.

Biomed Pharmacother 2019 Jan 5;109:2539-2547. Epub 2018 Dec 5.

Department of Clinical Pharmacology, SRM Medical College Hospital & Research Centre, Kattankulathur, Chennai, Tamil Nadu, 603203 India. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S07533322183639
Publisher Site
http://dx.doi.org/10.1016/j.biopha.2018.11.041DOI Listing
January 2019
17 Reads
2.023 Impact Factor

Synthetic approaches to isocarbacyclin and analogues as potential neuroprotective agents against ischemic stroke.

Bioorg Med Chem 2019 Jan 6;27(2):338-342. Epub 2018 Dec 6.

Department of Chemistry and Biochemistry, University of North Carolina at Greensboro, Greensboro 27402, USA. Electronic address:

Isocarbacyclin is a valuable synthetic analogue of prostacyclin with potential neuroprotective effects for the treatment of ischemic stroke. Herein, we describe the synthesis of isocarbacyclin and bicyclic analogues in only 7-10 steps, with the ω-side chain diversified at a late stage. A combination of new reaction design, function-oriented synthesis, and late-stage diversification led to a series of compounds that were tested for their neuroprotective activities. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S09680896183189
Publisher Site
http://dx.doi.org/10.1016/j.bmc.2018.12.010DOI Listing
January 2019
3 Reads

Protective Effects and Target Network Analysis of Ginsenoside Rg1 in Cerebral Ischemia and Reperfusion Injury: A Comprehensive Overview of Experimental Studies.

Cells 2018 Dec 12;7(12). Epub 2018 Dec 12.

Beijing Key Laboratory of Innovative Drug Discovery of Traditional Chinese Medicine (Natural Medicine) and Translational Medicine, Institute of Medicinal Plant Development, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing 100193, China.

Cerebral ischemia-reperfusion is a complicated pathological process. The injury and cascade reactions caused by cerebral ischemia and reperfusion are characterized by high mortality, high recurrence, and high disability. However, only a limited number of antithrombotic drugs, such as recombinant tissue plasminogen activator (r-TPA), aspirin, and heparin, are currently available for ischemic stroke, and its safety concerns is inevitable which associated with reperfusion injury and hemorrhage. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/cells7120270DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6316103PMC
December 2018
4 Reads

Nutrition, Energy Expenditure, Dysphagia, and Self-Efficacy in Stroke Rehabilitation: A Review of the Literature.

Brain Sci 2018 Dec 7;8(12). Epub 2018 Dec 7.

Department of Neurosurgery, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.

While significant research has been performed regarding the use of thrombolytic agents and thrombectomy in the setting of acute stroke, other factors, such as nutritional status of stroke patients, is a less explored topic. The topic of nutrition is critical to the discussion of stroke, as up to half of stroke survivors may be considered malnourished at discharge. Dysphagia, old age, restricted upper limb movement, visuospatial impairment, and depression are all important risk factors for malnutrition in this cohort. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/brainsci8120218DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6316714PMC
December 2018

Isosteviol Sodium Protects Neural Cells Against Hypoxia-Induced Apoptosis Through Inhibiting MAPK and NF-κB Pathways.

J Stroke Cerebrovasc Dis 2019 Jan 24;28(1):175-184. Epub 2018 Oct 24.

Institute of Biomedical and Pharmaceutical Sciences, Guangdong University of Technology, Guangzhou, China. Electronic address:

Background: Stevioside, isolated from the herb Stevia rebaudiana, has been widely used as a food sweetener all over the world. Isosteviol Sodium (STV-Na), an injectable formulation of isosteviol sodium salt, has been proved to possess much greater solubility and bioavailability and exhibit protective effects against cerebral ischemia injury in vivo by inhibiting neuron apoptosis. However, the underlying mechanisms of the neuroprotective effects STV-Na are still not completely known. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S10523057183052
Publisher Site
http://dx.doi.org/10.1016/j.jstrokecerebrovasdis.2018.09.020DOI Listing
January 2019
17 Reads

Intranasal Calcitonin Gene-Related Peptide Protects Against Focal Cerebral Ischemic Injury in Rats Through the Wnt/β-Catenin Pathway.

Med Sci Monit 2018 Dec 7;24:8860-8869. Epub 2018 Dec 7.

Key Lab of Cerebral Microcirculation in Universities of Shandong, Taishan Medical University, Taian, Shandong, China (mainland).

BACKGROUND Intranasal calcitonin gene-related peptide (CGRP) delivery offers a noninvasive method of bypassing the blood-brain barrier for the delivery of CGRP to the brain. Here, we first reported the therapeutic benefits of intranasal CGRP delivery in rats following middle cerebral artery occlusion (MCAO). MATERIAL AND METHODS Real-time quantitative polymerase chain reaction (RT-qPCR) assay, enzyme-linked immunosorbent assay (ELISA), rat MCAO model, TTC (2, 3, 5-triphenyltetrazolium chloride) staining, hematoxylin and eosin (H & E) staining, Morris water maze test, TUNEL assay, immunofluorescence, and western blot assay were used to investigate the role of CGRP in rats. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.12659/MSM.913777DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6295141PMC
December 2018
3 Reads

Neuroprotective Effect of Dichloromethane Extraction From Piper nigrum L. and Piper longum L. on Permanent Focal Cerebral Ischemia Injury in Rats.

J Stroke Cerebrovasc Dis 2019 Mar 8;28(3):751-760. Epub 2018 Dec 8.

School of Pharmacy, Ningxia Medical University, Yinchuan, China; Key Laboratory of Hui Ethnic Medicine Modernization, Ministry of Education, Yinchuan, China; Ningxia Engineering and Technology Research Center for Modernization of Hui Medicine, Yinchuan, China. Electronic address:

Background: Piper nigrum L. and Piper longum L. consist a classic formula in traditional Chinese Hui medicine and are widely used in treatment of stroke. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jstrokecerebrovasdis.2018.11.018DOI Listing
March 2019
1 Read

[Protective effect of picroside Ⅱ on the brain tissue through antioxidation in stroke rats].

Zhonghua Yi Xue Za Zhi 2018 Dec;98(45):3705-3710

Department of Pharmacy, Qingdao Municipal Hospital Affiliated to Qingdao University, Qingdao 266071, China.

To investigate the effect and mechanisms of picroside Ⅱ on the brain tissue after cerebral ischemia reperfusion(I/R) in rats. The middle cerebral artery occlusion(MCAO) rat model was established by inserting a monofilament into middle cerebral artery. The experimental rats were treated by injecting picroside Ⅱ intraperitoneally. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3760/cma.j.issn.0376-2491.2018.45.015DOI Listing
December 2018

Neuroprotective role of hypothermia in hypoxic-ischemic brain injury: combined therapies using estrogen.

Curr Neuropharmacol 2018 Dec 5. Epub 2018 Dec 5.

Laboratorio de Citoarquitectura y Plasticidad Neuronal, Instituto de Investigaciones Cardiológicas, Universidad de Buenos Aires, Consejo Nacional de Investigaciones Científicas y Técnicas, Buenos Aires. Argentina.

Hypoxic-ischemic brain injury is a complex network of factors, which is mainly characterized by a decrease in levels of oxygen concentration and blood flow, which lead to an inefficient supply of nutrients to the brain. Hypoxic-ischemic brain injury can be found in perinatal asphyxia and ischemic-stroke, which represent one of the main causes of mortality and morbidity in children and adults worldwide. Therefore, knowledge on underlying mechanisms triggering these insults may help establish neuroprotective treatments. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1570159X17666181206101314DOI Listing
December 2018
15 Reads

Potential of Exosomes for the Treatment of Stroke.

Cell Transplant 2018 Dec 6:963689718816990. Epub 2018 Dec 6.

1 Department of Anatomy, Histology and Embryology, Discipline of Neuroscience, Shanghai Jiao Tong University School of Medicine, Shanghai, China.

Stroke is the result of blockage or rupture of blood vessels in the brain and is the leading cause of death and disability in the world. Currently only a very limited number of therapeutic approaches are available for treatment of stroke patients, and the vast majority of neuroprotective agents that tested positively in pre-clinical studies failed in clinical trials. In recent years, the clinical value of the use of exosomes for stroke treatment has received widespread attention due their unique characteristics such as low immunogenicity, low toxicity and biodegradability, ability to cross the blood-brain barrier (BBB), and their important role in communication between cells. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0963689718816990DOI Listing
December 2018
33 Reads

Multiple Combination of Angelica gigas Extract and Mesenchymal Stem Cells Enhances Therapeutic Effect.

Biol Pharm Bull 2018 ;41(12):1748-1756

Department of Biology Education, College of Education, Pusan National University.

Alternative medicines attract attention because stroke is rarely expected to make a full recovery with the most advanced medical technology. Angelica gigas (AG) is a well-known herbal medicine as a neuroprotective agent. The present study introduced mesenchymal stem cells (MSCs) to identify for the advanced treatment of the cerebrovascular disease. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1248/bpb.b18-00193DOI Listing
March 2019
3 Reads

Pseudopterosin A ameliorates ischaemia-induced brain injury by acting on Akt signalling pathway.

Folia Neuropathol 2018 ;56(2):104-111

Introduction: Brain injury caused by ischaemic stroke is a major cause of disability and death throughout the world. The present study evaluates the neuroprotective effect of pseudopterosin A (PtA) against ischaemia-induced brain injury.

Material And Methods: Ischaemia was induced by pMCAO model, and rats were separated in to three groups. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5114/fn.2018.76614DOI Listing

Behavioral tests that reveal long-term deficits after permanent focal cerebral ischemia in mouse.

Behav Brain Res 2019 03 27;360:69-80. Epub 2018 Nov 27.

Equipe de recherche "Pharmacologie de la Circulation Cérébrale" EA 4475, Université Paris Descartes, Sorbonne Paris Cité, Faculté de Pharmacie de Paris, 75006 Paris, France. Electronic address:

Efforts are still needed regarding the research of therapeutics for ischemic stroke. While in experimental studies the protective effect of pharmacological agents is often highlighted by a reduction of the lesion size evaluated in the short term (days), in clinical studies a functional recovery of patients suffering from stroke is expected on the long-term (months and years). Long-term functional preclinical studies are highly recommended to evaluate potential neuroprotective agents for stroke, rather than an assessment of the infarction size at a short time point. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbr.2018.11.040DOI Listing
March 2019
2 Reads

Recent advances in the development of neuroprotective agents and therapeutic targets in the treatment of cerebral ischemia.

Eur J Med Chem 2019 Jan 7;162:132-146. Epub 2018 Nov 7.

Department of Neurosurgery, Changhai Hospital, Second Military Medical University, Shanghai, 200433, People's Republic of China. Electronic address:

Stroke is a central nervous system disease that seriously affects people's quality of life and has the second highest rate of morbidity and mortality in the world. At present, clinical treatment strategies for acute ischemic stroke are mainly thrombolytic and thrombectomy therapy. However, these strategies are not able to protect patients from ischemic injuries. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S02235234183096
Publisher Site
http://dx.doi.org/10.1016/j.ejmech.2018.11.014DOI Listing
January 2019
14 Reads

Propofol attenuates inflammatory damage on neurons following cerebral infarction by inhibiting excessive activation of microglia.

Int J Mol Med 2019 Jan 5;43(1):452-460. Epub 2018 Nov 5.

Department of Internal Neurology, The Second Affiliated Hospital, Hainan Medical University, Haikou, Hainan 570311, P.R. China.

The overall incidence rate of stroke is increasing worldwide. Inflammatory damage following a stroke is a leading cause for the poor prognosis and high disability rate observed in stroke patients. Microglia are considered to be the main causative agents of inflammatory injury following cerebral infarction, as they secrete various inflammatory cytokines and cytotoxic factors. Read More

View Article

Download full-text PDF

Source
http://www.spandidos-publications.com/10.3892/ijmm.2018.3974
Publisher Site
http://dx.doi.org/10.3892/ijmm.2018.3974DOI Listing
January 2019
14 Reads

Neuroprotective effects of midazolam on focal cerebral ischemia in rats through anti‑apoptotic mechanisms.

Int J Mol Med 2019 Jan 5;43(1):443-451. Epub 2018 Nov 5.

Department of Internal Neurology, The Second Affiliated Hospital of Hainan Medical University, Haikou, Hainan 570311, P.R. China.

Stroke is a cerebrovascular circulatory disorder and its high mortality rate represents a prominent threat to human health. Subsequent apoptosis and cytotoxicity are the main causes underlying the poor prognosis. Midazolam (MDZ) is a benzodiazepine drug that is clinically used during surgical procedures and for the treatment of insomnia, with a potential ability to treat stroke. Read More

View Article

Download full-text PDF

Source
http://www.spandidos-publications.com/10.3892/ijmm.2018.3973
Publisher Site
http://dx.doi.org/10.3892/ijmm.2018.3973DOI Listing
January 2019
20 Reads

Brain Peptides for the Treatment of Neuropsychiatric Disorders.

Curr Pharm Des 2018 ;24(33):3905-3917

Institute of Neurological Sciences and Psychiatry, Hacettepe University, Ankara, Turkey.

The realization of the importance of growth factors in adult CNS led to several studies investigating their roles in neuropsychiatric disorders. Based on the observations that chronic stress decreases brain-derived neurotrophic factor (BDNF) and antidepressant treatments reverse BDNF to normal levels, "neurotrophic hypothesis of depression" was proposed. Subsequent studies found that several other growth factors, including fibroblast growth factor (FGF), vascular endothelial growth factor, nerve growth factor were also decreased by chronic stress. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1381612824666181112112309DOI Listing
January 2018
15 Reads

Glycyrrhizin, an HMGB1 inhibitor, exhibits neuroprotective effects in rats after lithium-pilocarpine-induced status epilepticus.

J Pharm Pharmacol 2019 Mar 12;71(3):390-399. Epub 2018 Nov 12.

Department of Neurology, The First Affiliated Hospital of Xi'an Medical University, Xi'an, China.

Objectives: It has been proven that extracellular HMGB1 is involved in progression of neurologic disorders, such as stroke, traumatic brain injury, meningitis and epilepsy. Glycyrrhizin (GL) is a direct inhibitor of HMGB1, and blocks HMGB1 release into the extracellular. We aim in this study to investigate the neuroprotective effects of GL in a rat model after lithium-pilocarpine-induced status epilepticus (SE). Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/jphp.13040
Publisher Site
http://dx.doi.org/10.1111/jphp.13040DOI Listing
March 2019
17 Reads
2.161 Impact Factor

Neuroprotective Effects of Dibornol in Focal Cerebral Ischemia/Reperfusion in Rats.

Bull Exp Biol Med 2018 Nov 12;166(1):15-18. Epub 2018 Nov 12.

E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, Russia.

Neuroprotective activity of 2,6-diisobornyl-4-methylphenol (Dibornol) was studied under conditions of experimental focal cerebral ischemia/reperfusion modeled by intraluminal occlusion of the left middle cerebral artery for 1 h followed by recirculation. Dibornol administered in a dose of 10 mg/kg intragastrically 24 h and 30 min before and 24 h after focal ischemia/reperfusion modeling reduced the size of the brain infarction zone by 52% (48 h after recirculation) and neurological deficit by 1.7-2. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10517-018-4278-4DOI Listing
November 2018
1 Read

Trigonelline therapy confers neuroprotection by reduced glutathione mediated myeloperoxidase expression in animal model of ischemic stroke.

Life Sci 2019 Jan 7;216:49-58. Epub 2018 Nov 7.

Department of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research (NIPER), Ahmedabad, Gandhinagar, Gujarat, India. Electronic address:

Aim: Stroke is devastating with a limited choice of intervention. Many pharmacological entities are available but none of them have evolved successfully in counteracting the multifaceted molecular alterations following stroke. Myeloperoxidase (MPO) has been reported to play an important role in neuroinflammation following neurodegenerative diseases. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00243205183072
Publisher Site
http://dx.doi.org/10.1016/j.lfs.2018.11.014DOI Listing
January 2019
13 Reads

Mitochondrial protective effect of neferine through the modulation of nuclear factor erythroid 2-related factor 2 signalling in ischaemic stroke.

Br J Pharmacol 2019 Feb 18;176(3):400-415. Epub 2018 Dec 18.

State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao, China.

Background And Purpose: Ischaemic stroke is a leading cause of death and long-term disability. Promising neuroprotective compounds are urgently needed to overcome clinical therapeutic limitations. Neuroprotective agents are limited to single-target agents, which further limit their clinical effectiveness. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/bph.14537
Publisher Site
http://dx.doi.org/10.1111/bph.14537DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6329622PMC
February 2019
14 Reads

Cerebrolysin for the Treatment of Aneurysmal Subarachnoid Hemorrhage in Adults: A Retrospective Chart Review.

Adv Ther 2018 Dec 9;35(12):2224-2235. Epub 2018 Nov 9.

Department of Neurosurgery, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea.

Introduction: Cerebrolysin is a neuroprotective drug used in the treatment of acute ischemic stroke. To our knowledge, this drug has never been evaluated in patients with aneurysmal subarachnoid hemorrhage (SAH). The aim of this study was to evaluate the effect of Cerebrolysin in patients with aneurysmal SAH. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s12325-018-0832-8
Publisher Site
http://dx.doi.org/10.1007/s12325-018-0832-8DOI Listing
December 2018
20 Reads

The neurovascular protective effect of alogliptin in murine MCAO model and brain endothelial cells.

Biomed Pharmacother 2019 Jan 2;109:181-187. Epub 2018 Nov 2.

Department of Neurology, Xianyang Hospital of Yan'an University, Xianyang, 712000, China.

Endothelial damage and blood brain barrier disruption contribute to ischemic stroke and brain injury. Gliptins are a novel class of treatment agents for diabetes, and recent studies have linked the use of gliptins to neuroprotection. Alogliptin is a type of orally available gliptin that was approved for clinical use by the FDA in 2013. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S07533322183390
Publisher Site
http://dx.doi.org/10.1016/j.biopha.2018.10.064DOI Listing
January 2019
26 Reads

An Update on Pediatric Stroke Protocol.

Pediatr Emerg Care 2018 Nov;34(11):810-815

Fellows (McKinney, Magruder) and Professor (Abramo), Pediatric Emergency Medicine, University of Arkansas for Medical, Sciences/Arkansas Children's Hospital.

Pediatric stroke is relatively rare, with approximately 1000 childhood strokes in the United States per year. However, the occurrence of stroke in children leads to significant morbidity and mortality, warranting the development proven screening tools, protocols, and treatment options. Because significant delays in seeking medical attention can occur, time to recognition of pediatric stroke in the emergency department is uniquely challenging and critical. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PEC.0000000000001653DOI Listing
November 2018
1 Read
0.923 Impact Factor

The protective mechanisms of polydatin in cerebral ischemia.

Eur J Pharmacol 2019 Jan 30;842:133-138. Epub 2018 Oct 30.

School of Pharmacy, Monash University Malaysia, Malaysia.

The prevalence of stroke is high in both developing and developed nations. It causes a heavy social and financial burden to the sufferers and their caregivers. Thrombolytic therapy is the only pharmacological treatment available for stroke. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00142999183062
Publisher Site
http://dx.doi.org/10.1016/j.ejphar.2018.10.039DOI Listing
January 2019
16 Reads

8e Protects against Acute Cerebral Ischemia by Inhibition of PI3Kγ-Mediated Superoxide Generation in Microglia.

Molecules 2018 Oct 31;23(11). Epub 2018 Oct 31.

State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing 210009, Jiangsu, China.

The inflammatory response mediated by microglia plays a critical role in the progression of ischemic stroke. Phosphoinositide 3-kinase gamma (PI3Kγ) has been implicated in multiple inflammatory and autoimmune diseases, making it a promising target for therapeutic intervention. The aim of this study was to evaluate the efficacy of , a hydrogen sulfide (H₂S) releasing derivative of 3--butylphthalide (NBP), on brain damage and PI3Kγ signaling following cerebral ischemia injury. Read More

View Article

Download full-text PDF

Source
http://www.mdpi.com/1420-3049/23/11/2828
Publisher Site
http://dx.doi.org/10.3390/molecules23112828DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6278485PMC
October 2018
3 Reads

Acteoside Attenuates Oxidative Stress and Neuronal Apoptosis in Rats with Focal Cerebral Ischemia-Reperfusion Injury.

Biol Pharm Bull 2018 ;41(11):1645-1651

Department of Neurosurgery, Beijing Tian Tan Hospital, Capital Medical University.

Acteoside (ACT) has been shown to exert antioxidant and neuroprotective effects in neurodegenerative diseases. However, the effect of ACT on cerebral ischemia-reperfusion (I/R) injury is not yet clear. In this study, we found that ACT administration reduced infarct volume and brain edema, and improved neurological deficits, as indicated by the decreased modified neurological severity score. Read More

View Article

Download full-text PDF

Source
https://www.jstage.jst.go.jp/article/bpb/41/11/41_b18-00210/
Publisher Site
http://dx.doi.org/10.1248/bpb.b18-00210DOI Listing
February 2019
3 Reads